Maite Bourlon, Associate Professor and Head of the Urologic Oncology Clinic at Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, shared on X:
“DASL-HiCap trial
- ADT+Darolutamide+prostate/pelvis RT MFS-CI
- ≠ definition ‘very high risk’ and PSMA/PET not included
- Improved MFS-CI, PSA-PFS, CRPC, subsquent tx.
But final analysis and OS awaited!
- 3 studies: STAMPEDE, ENZARAD and DASL-HiCap. ≠ populations, ≠RT to pelvis, N1 benefit across trials.
- Good outcomes, need biomarkers”
You may also be interested in:
